Cardiometabolic disorders (hypertension, diabetes) are key modifiable risk factors for Alzheimer’s disease and related disorders. They often co-occur; yet, the extent to which they independently affect brain structure and function is unclear.
Objective:
We hypothesized their combined effect is greater in associations with cognitive function and neuroimaging biomarkers of white matter (WM) health and cerebral perfusion in a diverse older adult cohort.
Methods:
Participants aged 50-85 years received: clinical evaluation, oral glucose tolerance testing, neuroimaging, cognitive testing, and adjudication. Neuroimaging included: T1 (gray [GM]/WM segmentation, regional volumes/thicknesses); FLAIR (WM hyperintensity volume [WMHv]; arterial spin labeling (cerebral blood flow); diffusion tensor imaging (fractional anisotropy [FA]); and neurite orientation dispersion and density imaging (Free Water). Hypertension (HTN) and impaired glucose tolerance (IGT) were staged and cardiometabolic status was categorized (HTN only, IGT only, IGT+HTN, neither). Multivariable linear regression modeled associations with cognitive and neuroimaging measures (covariates: age, gender, race).
Results:
MRI was available for 478 participants (35% mild cognitive impairment, 10% dementia) with mean age 70±8 years, 74% with HTN, 61% with IGT, and 15% self-identified as Black/African-American. IGT+HTN was significantly associated with cognitive impairment, higher WM Free Water and WMHv, lower FA, and lower GM perfusion compared to neither factor. HTN alone was associated with poorer cognition and lower GM perfusion. Cardiometabolic factors were not associated with GM macrostructure (volumes, temporal lobe cortical thickness) or cognitive status.
Conclusion:
HTN and its co-occurrence with IGT (HTN+IGT) were associated with lower global cognitive performance and reduced GM perfusion and impaired WM microstructure.
ChengG, HuangC, DengH, WangH (2012) Diabetes as a risk factor for dementia and mild cognitive impairment: A meta-analysis of longitudinal studies. Intern Med J42, 484–491.
4.
McGrathER, BeiserAS, DeCarliC, PlourdeKL, VasanRS, GreenbergSM, SeshadriS (2017) Blood pressure from mid- to late life and risk of incident dementia. Neurology89, 2447–2454.
5.
ZhangJ, ChenC, HuaS, LiaoH, WangM, XiongY, CaoF (2017) An updated meta-analysis of cohort studies: Diabetes and risk of Alzheimer’s disease. Diabetes Res Clin Pract124, 41–47.
6.
LiX, SongD, LengSX (2015) Link between type 2 diabetes and Alzheimer’s disease: From epidemiology to mechanism and treatment. Clin Interv Aging10, 549–560.
7.
WhitmerRA, SidneyS, SelbyJ, JohnstonSC, YaffeK (2005) Midlife cardiovascular risk factors and risk of dementia in late life. Neurology64, 277–281.
8.
BiesselsGJ, NobiliF, TeunissenCE, SimoR, ScheltensP (2020) Understanding multifactorial brain changes in type 2 diabetes: A biomarker perspective. Lancet Neurol19, 699–710.
9.
WilliamsonJD, LaunerLJ, BryanRN, CokerLH, LazarRM, GersteinHC, MurrayAM, SullivanMD, HorowitzKR, DingJ, MarcovinaS, LovatoL, LovatoJ, MargolisKL, DavatzikosC, BarzilayJ, GinsbergHN, LinzPE, MillerME, Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Investigators (2014) Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: A randomized clinical trial. JAMA Intern Med174, 324–333.
10.
WilletteAA, XuG, JohnsonSC, BirdsillAC, JonaitisEM, SagerMA, HermannBP, La RueA, AsthanaS, BendlinBB (2013) Insulin resistance, brain atrophy, and cognitive performance in late middle-aged adults. Diabetes Care36, 443–449.
11.
LuchsingerJA, PaltaP, RipponB, SherwoodG, SotoL, CeballosF, LaingK, IgweK, HeH, RazlighiQ, TeresiJ, MorenoH, BrickmanAM (2020) Pre-diabetes, but not type 2 diabetes, is related to brain amyloid in late middle-age. J Alzheimers Dis75, 1241–1252.
12.
WillmannC, BrockmannK, WagnerR, KullmannS, PreisslH, SchnauderG, MaetzlerW, GasserT, BergD, EschweilerGW, MetzgerF, FallgatterAJ, HäringH-U, FritscheA, HeniM (2020) Insulin sensitivity predicts cognitive decline in individuals with prediabetes. BMJ Open Diabetes Res Care8, e001741.
13.
HughesTM, SinkKM (2016) Hypertension and its role in cognitive function: Current evidence and challenges for the future. Am J Hypertens29, 149–157.
14.
SPRINT MIND Investigators for the SPRINT Research GroupWilliamsonJD, PajewskiNM, AuchusAP, BryanRN, CheluneG, CheungAK, ClevelandML, CokerLH, CroweMG, CushmanWC, CutlerJA, DavatzikosC, DesiderioL, ErusG, FineLJ, GaussoinSA, HarrisD, HsiehMK, JohnsonKC, KimmelPL, TamuraMK, LaunerLJ, LernerAJ, LewisCE, Martindale-AdamsJ, MoyCS, NasrallahIM, NicholsLO, OparilS, OgrockiPK, RahmanM, RappSR, ReboussinDM, RoccoMV, SachsBC, SinkKM, StillCH, SupianoMA, SnyderJK, WadleyVG, WalkerJ, WeinerDE, WheltonPK, WilsonVM, WoolardN, WrightJT Jr, WrightCB (2019) Effect of intensive vs standard blood pressure control onprobable dementia: A randomized clinical trial. JAMA321, 553–561.
15.
SPRINT MIND Investigators for the SPRINT Research Group, NasrallahIM, PajewskiNM, AuchusAP, CheluneG, CheungAK, ClevelandML, CokerLH, CroweMG, CushmanWC, CutlerJA, DavatzikosC, DesiderioL, DoshiJ, ErusG, FineLJ, GaussoinSA, HarrisD, JohnsonKC, KimmelPL, Kurella TamuraM, LaunerLJ, LernerAJ, LewisCE, Martindale-AdamsJ, MoyCS, NicholsLO, OparilS, OgrockiPK, RahmanM, RappSR, ReboussinDM, RoccoMV, SachsBC, SinkKM, StillCH, SupianoMA, SnyderJK, WadleyVG, WalkerJ, WeinerDE, WheltonPK, WilsonVM, WoolardN, WrightJT Jr, WrightCB, WilliamsonJD, BryanRN (2019) Association of intensive vs standard blood pressure control with cerebral white matter lesions. JAMA322, 524–534.
16.
MuntnerP, CareyRM, GiddingS, JonesDW, TalerSJ, WrightJTJr., WheltonPK (2018) Potential U.S. population impact of the 2017 ACC/AHA High Blood Pressure Guideline. J Am Coll Cardiol71, 109–118.
17.
SpanakisEK, GoldenSH (2013) Race/ethnic difference in diabetes and diabetic complications. Curr Diab Rep13, 814–823.
18.
LevineDA, GrossAL, BricenoEM, TiltonN, KabetoMU, HingtgenSM, GiordaniBJ, SussmanJB, HaywardRA, BurkeJF, ElkindMSV, ManlyJJ, MoranAE, KulickER, GottesmanRF, WalkerKA, YanoY, GaskinDJ, SidneyS, YaffeK, SaccoRL, WrightCB, RogerVL, AllenNB, GaleckiAT (2020) Association between blood pressure and later-life cognition among black and white individuals. JAMA Neurol77, 810–819.
19.
WeintraubS, BesserL, DodgeHH, TeylanM, FerrisS, GoldsteinFC, GiordaniB, KramerJ, LoewensteinD, MarsonD, MungasD, SalmonD, Welsh-BohmerK, ZhouXH, ShirkSD, AtriA, KukullWA, PhelpsC, MorrisJC (2018) Version 3 of the Alzheimer Disease Centers’ Neuropsychological Test Battery in the Uniform Data Set (UDS). Alzheimer Dis Assoc Disord32, 10–17.
20.
SachsBC, SteenlandK, ZhaoL, HughesTM, WeintraubS, DodgeHH, BarnesLL, CraftS, ParkerML, GoldsteinFC (2020) Expanded demographic norms for version 3 of the Alzheimer Disease Centers’ Neuropsychological Test Battery in the Uniform Data Set. Alzheimer Dis Assoc Disord34, 191–197.
21.
PappKV, RentzDM, OrlovskyI, SperlingRA, MorminoEC (2017) Optimizing the preclinical Alzheimer’s cognitive composite with semantic processing: The PACC5. Alzheimers Dement (N Y)3, 668–677.
22.
AlbertMS, DeKoskyST, DicksonD, DuboisB, FeldmanHH, FoxNC, GamstA, HoltzmanDM, JagustWJ, PetersenRC, SnyderPJ, CarrilloMC, ThiesB, PhelpsCH (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 270–279.
23.
McKhannGM, KnopmanDS, ChertkowH, HymanBT, JackCRJr., KawasCH, KlunkWE, KoroshetzWJ, ManlyJJ, MayeuxR, MohsRC, MorrisJC, RossorMN, ScheltensP, CarrilloMC, ThiesB, WeintraubS, PhelpsCH (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 263–269.
ZhangH, SchneiderT, Wheeler-KingshottCA, AlexanderDC (2012) NODDI: Practical in vivo neurite orientation dispersion and density imaging of the human brain. Neuroimage61, 1000–1016.
BuxtonRB, FrankLR, WongEC, SiewertB, WarachS, EdelmanRR (1998) A general kinetic model for quantitative perfusion imaging with arterial spin labeling. Magn Reson Med40, 383–396.
34.
WongEC (2005) Quantifying CBF with pulsed ASL: Technical and pulse sequence factors. J Magn Reson Imaging22, 727–731.
35.
AlateeqK, WalshEI, CherbuinN (2021) Higher blood pressure is associated with greater white matter lesions and brain atrophy: A systematic review with meta-analysis. J Clin Med10, 637.
36.
DueringM, FinsterwalderS, BaykaraE, TuladharAM, GesierichB, KoniecznyMJ, MalikR, FranzmeierN, EwersM, JouventE, BiesselsGJ, SchmidtR, de LeeuwF-E, PasternakO, DichgansM (2018) Free water determines diffusion alterations and clinical status in cerebral small vessel disease. Alzheimers Dement14, 764–774.
37.
van BloemendaalL, IjzermanRG, Ten Kulve JS, BarkhofF, DiamantM, VeltmanDJ, van DuinkerkenE (2016) Alterations in white matter volume and integrity in obesity and type 2 diabetes. Metab Brain Dis31, 621–629.
38.
ZhouJB, TangXY, HanYP, LuoFQ, CardosoMA, QiL (2020) Prediabetes and structural brain abnormalities: Evidence from observational studies. Diabetes Metab Res Rev36, e3261.
39.
van Agtmaal MJM, HoubenA, de WitV, HenryRMA, SchaperNC, DagneliePC, van der KallenCJ, KosterA, SepSJ, KroonAA, JansenJFA, HofmanPA, BackesWH, SchramMT, StehouwerCDA (2018) Prediabetes is associated with structural brain abnormalities: The Maastricht Study. Diabetes Care41, 2535–2543.
40.
TiehuisAM, van der GraafY, MaliWP, VinckenK, MullerM, GeerlingsMI, GroupSS (2014) Metabolic syndrome, prediabetes, and brain abnormalities on MRI in patients with manifest arterial disease: The SMART-MR study. Diabetes Care37, 2515–2521.
41.
LaneCA, BarnesJ, NicholasJM, SudreCH, CashDM, ParkerTD, MaloneIB, LuK, JamesSN, KeshavanA, Murray-SmithH, WongA, BuchananSM, KeussSE, GordonE, CoathW, BarnesA, DicksonJ, ModatM, ThomasD, CrutchSJ, HardyR, RichardsM, FoxNC, SchottJM (2019) Associations between blood pressure across adulthood and late-lifebrain structure and pathology in the neuroscience substudy of the1946 British birth cohort (Insight 46): An epidemiological study. Lancet Neurol18, 942–952.
42.
LangbaumJB, ChenK, LaunerLJ, FleisherAS, LeeW, LiuX, ProtasHD, ReederSA, BandyD, YuM, CaselliRJ, ReimanEM (2012) Blood pressure is associated with higher brain amyloid burden and lower glucose metabolism in healthy late middle-age persons. Neurobiol Aging33, 827e811–829.
43.
AbnerEL, NelsonPT, KryscioRJ, SchmittFA, FardoDW, WoltjerRL, CairnsNJ, YuL, DodgeHH, XiongC, MasakiK, TyasSL, BennettDA, SchneiderJA, ArvanitakisZ (2016) Diabetes is associated with cerebrovascular but not Alzheimer’s disease neuropathology. Alzheimers Dement12, 882–889.
44.
ToledoJB, ToledoE, WeinerMW, JackCRJr., JagustW, LeeVM, ShawLM, TrojanowskiJQ, Alzheimer’s Disease Neuroimaging I (2012) Cardiovascular risk factors, cortisol, and amyloid-beta deposition in Alzheimer’s Disease Neuroimaging Initiative. Alzheimers Dement8, 483–489.
45.
GottesmanRF, SchneiderAL, AlbertM, AlonsoA, Bandeen-RocheK, CokerL, CoreshJ, KnopmanD, PowerMC, RawlingsA, SharrettAR, WruckLM, MosleyTH (2014) Midlife hypertension and 20-year cognitive change: The Atherosclerosis Risk in Communities Neurocognitive Study. JAMA Neurol71, 1218–1227.
46.
HughesTM, KullerLH, Barinas-MitchellEJM, MackeyRH, McDadeEM, KlunkWE, AizensteinHJ, CohenAD, SnitzBE, MathisCA, DeKoskyST, LopezOL (2013) Pulse wave velocity is associated with β-amyloid deposition in the brains of very elderly adults. Neurology81, 1711–1718.
PetrieJR, GuzikTJ, TouyzRM (2018) Diabetes, hypertension, and cardiovascular disease: Clinical insights and vascular mechanisms. Can J Cardiol34, 575–584.
51.
CheungBM, LiC (2012) Diabetes and hypertension: Is there a common metabolic pathway? . Curr Atheroscler Rep14, 160–166.
52.
YaoJ, GongX, ShiX, FanS, ChenJ, ChenQ (2020) The efficacy of angiotensin converting enzyme inhibitors versus angiotensin II receptor blockers on insulin resistance in hypertensive patients: A protocol for a systematic review and meta-analysis. Medicine (Baltimore)99, e20674.
53.
LaunerLJ, MillerME, WilliamsonJD, LazarRM, GersteinHC, MurrayAM, SullivanM, HorowitzKR, DingJ, MarcovinaS, LovatoLC, LovatoJ, MargolisKL, O’ConnorP, LipkinEW, HirschJ, CokerL, MaldjianJ, SunshineJL, TruwitC, DavatzikosC, BryanRN, ACCORD MIND investigators (2011) Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): A randomised open-label substudy. Lancet Neurol10, 969–977.
